Hypothesis

Age‑related extracellular matrix stiffening in the adrenal medulla‑cortex interface activates perivascular fibroblasts to secrete TGF‑β1, which drives senescence‑associated secretory phenotype (SASP) in zona reticularis (ZR) progenitors, selectively impairing their proliferation and survival while sparing zona fasciculata (ZF) cells.

Mechanistic Rationale

1. With ageing, collagen cross‑linking increases in the adrenal capsule and peri‑adrenal fat, raising tissue tensile strength (4).
2. Stiff matrices potentiate integrin‑αvβ3 signaling in resident fibroblasts, triggering a mechanotransductive cascade that elevates active TGF‑β1 release (5).
3. TGF‑β1 is a potent inducer of p16^INK4a^ and p21^CIP1^ expression, hallmark markers of cellular senescence, and stimulates SASP factors such as IL‑6 and PAI‑1 that reinforce a pro‑inflammatory niche (2).
4. The ZR resides closer to the medulla and receives higher catecholamine exposure, which sensitizes its stromal fibroblasts to TGF‑β signaling via β‑adrenergic receptor cross‑talk, rendering ZR progenitors more susceptible to senescence‑induced apoptosis (6).
5. In contrast, ZF cells are anchored deeper within the cortex, experience lower mechanical strain, and express higher levels of the TGF‑β decoy receptor BMPR‑II, conferring resistance to fibroblast‑derived TGF‑β1 (1).

Together, this creates a zone‑specific microenvironments where fibroblast‑derived TGF‑β drives ZR cell loss, explaining the selective atrophy and the preserved or expanded ZF observed in ageing adrenals.

Testable Predictions

• Prediction 1: Aged adrenal biopsies will show elevated collagen cross‑linking (hydroxylysyl pyridinoline) and increased α‑SMA^+ fibroblast density specifically at the medulla‑cortex junction compared with young tissue.
• Prediction 2: ZR progenitor cultures exposed to conditioned medium from aged adrenal fibroblasts will exhibit increased SA‑β‑gal activity and reduced Ki‑67 labeling, effects blocked by neutralizing TGF‑β1 antibody or fibroblast‑specific TGF‑β1 knock‑down.
• Prediction 3: Genetic attenuation of fibroblast TGF‑β1 secretion (e.g., Col1a2‑CreERT2;Tgfb1^fl/fl mice) will preserve ZR thickness and DHEA output in aged mice, without altering ZF corticosterone production.
• Prediction 4: Pharmacologic LOX inhibition (β‑aminopropionitrile) administered mid‑life will reduce adrenal stiffness, lower fibroblast TGF‑β1 release, and attenuate the age‑related rise in cortisol:DHEA ratio.

Experimental Approach

1. Human tissue: Quantify collagen cross‑links via HPLC‑derived hydroxylysyl pyridinoline in microdissected adrenal zones from donors stratified by age (n=30 per group). Immunostain for α‑SMA, p16, and CYB5A to correlate fibroblast activation with ZR senescence markers.
2. Mouse models: Induce fibroblast‑specific Tgfb1 deletion in aged (18‑month) mice; measure ZR area (histology), plasma DHEAS, and corticosterone after ACTH challenge. Include LOX‑treated cohorts.
3. In vitro: Isolate adrenal fibroblasts from young and old donors, culture in tunable stiffness hydrogels (0.5–20 kPa). Assess TGF‑β1 secretion (ELISA) and its impact on co‑cultured ZR stem‑like cells (sorted via CYB5A^+).

Falsifiability

If aged adrenals show no increase in matrix cross‑linking or fibroblast activation, or if ZR senescence persists despite fibroblast‑specific TGF‑β1 blockade, the hypothesis would be falsified. Conversely, confirming any of the predictions would support the mechanobiological link between adrenal stiffening, fibroblast‑mediated TGF‑β signaling, and selective ZR senescence.